[Corrections] Correction to Lancet Oncol 2023; 24: 228–38

Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol 2023; 24: 228–38—In figure 3 of this Article, the data label has been corrected to report “overall survival”. This correction has been made to the online version as of March 27, 2023.